×
About 2,739 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  1,085 results

Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Co...
https://doi.org/10.1016/j.jid.2020.12.030
The Journal of Investigative Dermatology; Aberer E, Sperr WR et. al.

Feb 13th, 2021 - Mastocytosis is a rare neoplasm characterized by expansion and accumulation of mast cells in various organ systems. Systemic mastocytosis (SM) may or may not presents with cutaneous lesions. To examine the frequency and clinical impact of cutaneou...

Aggressive systemic mastocytosis presenting as rapidly progressive ascites, generalised...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872913
BMJ Case Reports; Arun VA, Soni D et. al.

Feb 9th, 2021 - Rapidly progressive ascites is a frequent clinical manifestation of advanced abdominal malignancies or portal hypertension due to liver diseases. We report a case of 61-year-old man who presented with rapidly progressive ascites. The presence of a...

Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and mana...
https://doi.org/10.1002/ajh.26118
American Journal of Hematology; Pardanani A

Feb 1st, 2021 - Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in extra-cutaneous organs. The major criterion is presence of multifocal clusters of spindled MC in the bone marrow. Minor diagnostic criteria include eleva...

Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cel...
https://doi.org/10.1182/blood.2019004509
Blood Toledo MAS, Gatz M et. al.

Jan 29th, 2021 - The KIT D816V mutation is found in more than 80% of patients with systemic mastocytosis (SM) and is key to neoplastic mast cell (MC) expansion and accumulation in affected organs. KIT D816V therefore represents a prime therapeutic target for SM. H...

Challenging diagnosis of indolent systemic mastocytosis isolated to the GI tract.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843311
BMJ Case Reports; Horton L, Al-Kourainy N et. al.

Jan 28th, 2021 - Mastocytosis is a rare group of disorders that presents with heterogenous phenotypes depending on the organ system involved. In the absence of cutaneous involvement-mast cell aggregates that may present as papules, nodules or plaques-classically a...

see more →

Guidelines  2 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

see more →

Drugs  251 results see all →

Clinicaltrials.gov  1,365 results

Ranitidine - ranitidine tablet, film coated-A-S Medication Solutions
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d0e44d3-615c-4ac6-8e03-eb19ec42e6d4

Feb 22nd, 2021 - Ranitidine tablets USP are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more t...

Ranitidine - ranitidine tablet-NuCare Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=518870ec-d998-5c2d-e054-00144ff88e88

Feb 22nd, 2021 - Ranitidine Tablets, USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more th...

Ranitidine - ranitidine tablet, film coated-NuCare Pharmaceuticals,Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f88ce13-e82e-ca51-e053-2995a90a1e83

Feb 18th, 2021 - Ranitidine tablets USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more tha...

Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Co...
https://doi.org/10.1016/j.jid.2020.12.030
The Journal of Investigative Dermatology; Aberer E, Sperr WR et. al.

Feb 13th, 2021 - Mastocytosis is a rare neoplasm characterized by expansion and accumulation of mast cells in various organ systems. Systemic mastocytosis (SM) may or may not presents with cutaneous lesions. To examine the frequency and clinical impact of cutaneou...

Ranitidine - ranitidine tablet, film coated-NuCare Pharmaceuticals,Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aa1bf9b-0b71-226b-e054-00144ff8d46c

Feb 10th, 2021 - Ranitidine tablets USP are indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more tha...

see more →

News  31 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

Avapritinib yields high response rate in patients with systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/153966/myelodysplastic-syndrome/avapritinib-yields-high-response-rate
Andrew D. Bowser

Dec 10th, 2017 - ATLANTA – An oral investigational drug with specific activity against a mutation frequently found in advanced systemic mastocytosis (ASM) produced clinical responses in the majority treated patients, according to preliminary data presented at the.

see more →

Patient Education  5 results see all →